Animal Tissue Cell Culture Patents (Class 435/70.3)
  • Patent number: 11384352
    Abstract: Provided herein, in some embodiments, are methods of purifying a nucleic acid preparation. The methods may comprise contacting a nucleic acid preparation comprising messenger ribonucleic acid with an RNase III enzyme that is immobilized on a solid support and binds to double-stranded RNA contaminants.
    Type: Grant
    Filed: December 13, 2017
    Date of Patent: July 12, 2022
    Assignee: ModernaTX, Inc.
    Inventor: Edward J. Miracco
  • Patent number: 11351246
    Abstract: The invention relates a recombinant measles virus plasmid capable of expressing a human telomerase reverse transcriptase (hTERT) protein fused at N-terminus with a protein enhancing addressing of the hTERT protein to proteasome. The invention further relates to a vaccine comprising said plasmid or particles rescued therefrom, and uses thereof, especially in preventing or treating a tumor in a patient.
    Type: Grant
    Filed: May 7, 2018
    Date of Patent: June 7, 2022
    Assignees: INVECTYS SAS, INSTITUT PASTEUR, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Pierre Langlade Demoyen, Frédéric Tangy, Elodie Pliquet
  • Patent number: 11001623
    Abstract: Perfusion media are disclosed providing excellent cell density, titer and product quality for production of a therapeutic protein in a perfusion process.
    Type: Grant
    Filed: August 13, 2018
    Date of Patent: May 11, 2021
    Assignee: Coherus BioSciences, Inc.
    Inventors: Ela Puchacz, James Russell Grove
  • Patent number: 10793877
    Abstract: The invention relates to a recombinant measles virus expressing a heterologous amino acid sequence derived from an antigen of a determined RNA virus, said recombinant measles virus being capable of eliciting a humoral and/or cellular immune response against measles virus or against said RNA virus or against both measles virus and against said RNA virus. It also relates to the use of said recombinant measles virus for the preparation of immunogenic composition.
    Type: Grant
    Filed: November 18, 2019
    Date of Patent: October 6, 2020
    Assignees: INSTITUT PASTEUR, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIEQUE
    Inventors: Frederic Tangy, Clarisse Lorin, Lucile Mollet, Frederic Delebecque
  • Patent number: 10703789
    Abstract: A pharmaceutical composition which has a plurality of lipid nanoparticles that has a mean particle size of between 80 nm and 160 nm and contains a modified mRNA encoding a polypeptide. The lipid nanoparticles include a cationic lipid, a neutral lipid, a cholesterol, and a PEG lipid. The mRNA contains a 5?-cap, 5?-UTR, N1-methyl-pseudouridine, a 3?-UTR, and a poly-A region with at least 100 nucleotides.
    Type: Grant
    Filed: June 12, 2019
    Date of Patent: July 7, 2020
    Assignee: ModernaTX, Inc.
    Inventors: Antonin De Fougerolles, Justin Guild
  • Patent number: 10577403
    Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules.
    Type: Grant
    Filed: June 12, 2019
    Date of Patent: March 3, 2020
    Assignee: ModernaTX, Inc.
    Inventors: Antonin De Fougerolles, Justin Guild
  • Patent number: 10570434
    Abstract: The subject invention pertains to methods and apparatus for the production and purification of cell products, such as immunoglobulins. One aspect of the invention is an integrated cell culture and purification apparatus for the growth and maintenance of cells and the harvest and purification of cell products, such as immunoglobulins. Thus, the apparatus integrates a cell culture function with a purification function. Other aspects of the invention pertain to an automated method for producing immunogenic compositions such as vaccines.
    Type: Grant
    Filed: January 31, 2018
    Date of Patent: February 25, 2020
    Assignee: BIOVEST INTERNATIONAL, INC.
    Inventors: Mark Hirschel, Robert J. Wojciechowski, Grant Adams, Darrell P. Page, Kimberly Arneson, Jeff Jorgensen, Scott Waniger
  • Patent number: 10501512
    Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules.
    Type: Grant
    Filed: March 9, 2013
    Date of Patent: December 10, 2019
    Assignee: ModernaTX, Inc.
    Inventors: Antonin De Fougerolles, Justin Guild
  • Patent number: 10457947
    Abstract: A peptide nucleic acid (PNA) referred to herein as Sweet-P, compositions comprising the methods of making the same, mid methods of using the same, are described.
    Type: Grant
    Filed: March 7, 2017
    Date of Patent: October 29, 2019
    Assignee: The University of Toldeo
    Inventors: Terry D. Hinds, Jr., Lucien McBeth
  • Patent number: 10421949
    Abstract: Provided herein are methods of culturing an adherent mammalian cell in a shake tube using a plurality of microcarriers and batch re-feed perfusion, and various methods that utilize these culturing methods.
    Type: Grant
    Filed: February 21, 2014
    Date of Patent: September 24, 2019
    Assignee: Genzyme Corporation
    Inventors: Jianguo Yang, Yang Yang
  • Patent number: 10385106
    Abstract: The present disclosure describes compositions including polynucleotides encoding polypeptides which have been chemically modified by replacing the uridines with 5-methoxy-uridines to improve the compositions, engagement with translational machinery, mRNA half-life, translation efficiency, immune evasion, protein production capacity, secretion efficiency, accessibility to circulation, protein half-life and/or modulation of a cell's status, protein half-life and/or modulation of a cell's status function, and/or activity.
    Type: Grant
    Filed: January 4, 2016
    Date of Patent: August 20, 2019
    Assignee: ModernaTX, Inc.
    Inventors: Antonin De Fougerolles, Justin Guild
  • Patent number: 10335498
    Abstract: The present disclosure provides compositions and methods useful for tissue engineering including a composition having chemically modified RNA (cmRNA) encapsulated in or complexed with a non-viral delivery vehicle and a biocompatible, bioresorbable scaffold and methods of using the composition to regenerate, for example, bone tissue.
    Type: Grant
    Filed: December 29, 2015
    Date of Patent: July 2, 2019
    Assignee: University of Iowa Research Foundation
    Inventors: Satheesh Elangovan, Sheetal Reginald R D'mello, Anh-Vu T Do, Liu Hong, Behnoush Khorsand-Sourkohi, Aliasger K Salem, Michael Kormann
  • Patent number: 9827332
    Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules.
    Type: Grant
    Filed: November 13, 2015
    Date of Patent: November 28, 2017
    Assignee: ModernaTX, Inc.
    Inventors: Stephane Bancel, Tirtha Chakraborty, Antonin de Fougerolles, Sayda M. Elbashir, Jeff Lynn Ellsworth, Kenechi Ejebe, Justin Guild, Matthias John, Paul Hatala, Atanu Roy, Jason P. Schrum, Susan Whoriskey, Kristy M. Wood
  • Patent number: 9828416
    Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules.
    Type: Grant
    Filed: June 25, 2015
    Date of Patent: November 28, 2017
    Assignee: ModernaTX, Inc.
    Inventors: Stephane Bancel, Tirtha Chakraborty, Antonin de Fougerolles, Sayda M. Elbashir, Matthias John, Atanu Roy, Susan Whoriskey, Kristy M. Wood, Paul Hatala, Jason P. Schrum, Kenechi Ejebe, Jeff Lynn Ellsworth, Justin Guild
  • Patent number: 9814760
    Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules.
    Type: Grant
    Filed: October 8, 2015
    Date of Patent: November 14, 2017
    Assignee: ModernaTX, Inc.
    Inventors: Stephane Bancel, Tirtha Chakraborty, Antonin de Fougerolles, Sayda M. Elbashir, Matthias John, Atanu Roy, Susan Whoriskey, Kristy M. Wood, Paul Hatala, Jason P. Schrum, Kenechi Ejebe, Jeff Lynn Ellsworth, Justin Guild
  • Patent number: 9802993
    Abstract: The present invention provides a cell capable of high-yield production of polypeptides and a method for producing the same. The present invention relates to a method for producing a cell capable of high-yield production of a desired polypeptide, wherein a strongly taurine transporter-expressing cell into which DNA encoding the desired polypeptide has been introduced is cultured in the presence of a high concentration of methotrexate and a cell capable of high-yield production of the desired polypeptide is selected from among surviving cells.
    Type: Grant
    Filed: October 14, 2008
    Date of Patent: October 31, 2017
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Hisahiro Tabuchi, Tomoya Sugiyama
  • Patent number: 9701944
    Abstract: The invention relates to a cDNA molecule which encodes the nucleotide sequence of the full length antigenomic (+)RNA strand of a measles virus (MV) originating from an approved vaccine strain. It also concerns the preparation of immunogenic compositions using said cDNA.
    Type: Grant
    Filed: March 24, 2015
    Date of Patent: July 11, 2017
    Assignees: Institut Pasteur, Centre National de la Recherche Scientifique
    Inventors: Frederic Tangy, Chantal Combredet, Valerie Labrousse-Najburg, Michel Brahic
  • Patent number: 9284374
    Abstract: The present invention provides a method capable of producing a natural or recombinant protein in high yield. The present invention relates to a method of producing a polypeptide, comprising culturing a cell which strongly expresses alanine aminotransferase and has a transferred DNA encoding a desired polypeptide and thereby allowing the cell to produce the polypeptide.
    Type: Grant
    Filed: March 26, 2014
    Date of Patent: March 15, 2016
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Hisahiro Tabuchi, Tomoya Sugiyama
  • Patent number: 9238687
    Abstract: The present invention provides a method capable of producing a natural or recombinant protein at low cost. The present invention relates to a method of producing a polypeptide, comprising culturing a cell which strongly expresses a taurine transporter and has a transferred DNA encoding a desired polypeptide and thereby allowing the cell to produce the polypeptide. Hamster taurine transporter, a DNA encoding the same, a recombinant vector and a transformed cell are also provided.
    Type: Grant
    Filed: April 12, 2007
    Date of Patent: January 19, 2016
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Hisahiro Tabuchi, Tomoya Sugiyama, Saeko Tanaka, Satoshi Tainaka
  • Patent number: 9034649
    Abstract: This invention relates to a method for producing a protein of interest, comprising introducing a protein expression vector which comprises a gene fragment a gene fragment comprising a DNA encoding a protein of interest and a selectable marker gene and transposon sequences at both terminals of the gene fragment, into a suspension mammalian cell; integrating the gene fragment inserted between a pair of the transposon sequences, into a chromosome of the mammalian cell to obtain a mammalian cell capable of expressing the protein of interest; and suspension-culturing the mammalian cell; and a suspension mammalian cell capable of expressing the protein of interest.
    Type: Grant
    Filed: June 11, 2010
    Date of Patent: May 19, 2015
    Assignees: Inter-University Research Institute Corporation Research Organization of Information and Systems, KYOWA HAKKO KIRIN CO., LTD
    Inventors: Koichi Kawakami, Keina Yamaguchi, Risa Ogawa, Masayoshi Tsukahara
  • Publication number: 20150111252
    Abstract: The subject invention pertains to methods and apparatus for the production and purification of cell products, such as immunoglobulins. One aspect of the invention is an integrated cell culture and purification apparatus for the growth and maintenance of cells and the harvest and purification of cell products, such as immunoglobulins. Thus, the apparatus integrates a cell culture function with a purification function. Other aspects of the invention pertain to an automated method for producing immunogenic compositions such as vaccines.
    Type: Application
    Filed: October 17, 2014
    Publication date: April 23, 2015
    Inventors: MARK HIRSCHEL, ROBERT J. WOJCIECHOWSKI, MICHAEL J. GRAMER, GRANT ADAMS, DARRELL P. PAGE, CHAD SINKLER, KEVIN TACHENY, KIMBERLY ARNESON, JEFF JORGENSEN, SCOTT WANIGER
  • Publication number: 20150110775
    Abstract: The instant invention relates to modulated lysine variant species compositions comprising a protein, e.g., an antibody, or antigen-binding portion thereof, and methods, e.g., cell culture and/or protein purification methods, for producing such modulated lysine variant species compositions. Methods for using such compositions to treat a disorder, e.g., a disorder in which TNF? is detrimental, are also provided.
    Type: Application
    Filed: November 12, 2013
    Publication date: April 23, 2015
    Inventors: Kartik SUBRAMANIAN, Mayda PEREZ THIELE, Xiaobei ZENG, Chee Furng WONG, Zehra KAYMAKCALAN, Ying JING, Christopher CHUMSAE
  • Publication number: 20150110753
    Abstract: The present invention provides biomatrix scaffolds, a tissue extract enriched for extracellular matrix components and bound growth factors, cytokines and hormones, and methods of making and using same.
    Type: Application
    Filed: August 8, 2014
    Publication date: April 23, 2015
    Applicant: THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
    Inventors: Yunfang WANG, Lola Cynthia McAdams REID, Mitsuo YAMAUCHI, Cai-Bin CUI, Andrew Zhuang WANG, Michael Edward WERNER
  • Patent number: 9012180
    Abstract: An improved system for large scale production of polypeptides in cell culture is provided. In accordance with the present invention, cells expressing a polypeptide of interest are grown in media that contain copper, glutamate or both. The use of such a system allows production of polypeptides in which misfolding and/or aggregation are reduced, and in which total glycosylation is increased. Polypeptides expressed in accordance with the present invention may be advantageously used in the preparation of pharmaceutical, agricultural or other commercial compositions.
    Type: Grant
    Filed: February 29, 2008
    Date of Patent: April 21, 2015
    Assignee: Wyeth LLC
    Inventors: Denis Drapeau, Jessica Snow, Gregory Hiller, Yen Tung Luan
  • Patent number: 9012220
    Abstract: The present invention relates to cells capable of expressing IDO, nucleic acid constructs for expression of IDO, cells comprising said constructs and methods of utilizing said cells in the treatment of diseases. In particular the present invention relates to cells which express IDO in the absence of exposure to IFN-gamma, and to their use in preparation and/or generation of immunomodulatory cells specific for an antigen.
    Type: Grant
    Filed: November 6, 2009
    Date of Patent: April 21, 2015
    Assignee: Cellerix S.A.
    Inventors: Dirk Buescher, Olga De La Rosa, Eleuterio Lombardo
  • Publication number: 20150104477
    Abstract: A method of inducing a specific immune response in a mammal, comprising: providing a first composition comprising isolated ubiquitinylated proteins in solution in the absence of membrane bound organelles, the isolated ubiquitinylated proteins comprising one or more specific antigens, and further comprising a threshold quantity of polyubiquitinylated short-lived proteins and polyubiquitinylated defective ribosomal products. The isolated ubiquitinylated proteins are affinity-purified from tumor-derived cells grown in culture, the tumor-derived cells being inhibited from degrading ubiquitinylated proteins via the proteasome while being grown in culture. In this way, highly immunogenic short-lived proteins and defective ribosomal products may be loaded onto dendritic cells for cross-presentation and priming of antigen-specific T cells restricted by either classical or non-classical MHC.
    Type: Application
    Filed: October 10, 2014
    Publication date: April 16, 2015
    Inventors: Christopher Twitty, Erik LeShane, Bernard Fox, Hong-Ming Hu, Guangjie Yu
  • Publication number: 20150104830
    Abstract: The invention provides a process for generating an avian cell line of duck origin by a process comprising: —cultivating embryonic avian cells in cell culture medium, preferably comprising fetal calf serum (FBS) for more than 40 passages while reducing the concentration of FBS to 1-2% vol/vol FBS, —transferring passaged cells into cell culture medium having 0% FBS, —resulting in the generation of a non-embryonic avian cell line suitable for non-adherent growth, i.e. for growth in suspended culture.
    Type: Application
    Filed: May 2, 2013
    Publication date: April 16, 2015
    Inventors: Manfred Wirth, Lijing Sun, Zhiguo Su, Roland Riebe, Jaeger Volker, Nadine Konisch
  • Patent number: 9005925
    Abstract: The invention relates to a cDNA molecule which encodes the nucleotide sequence of the full length antigenomic (+)RNA strand of a measles virus (MV) originating from an approved vaccine strain. It also contains the preparation of immunogenic compositions using said cDNA.
    Type: Grant
    Filed: July 24, 2008
    Date of Patent: April 14, 2015
    Assignees: Institut Pasteur, Centre National de la Recherche Scientifique
    Inventors: Frédéric Tangy, Chantal Combredet, Valérie Labrousse-Najburg, Michel Brahic
  • Patent number: 9005926
    Abstract: The present invention pertains to methods of preventing and eliminating trisulfide bonds in proteins such as antibodies. In one embodiment, trisulfide bonds in proteins are converted to disulfide bonds as part of chromatographic purification procedures. In another embodiment, the formation of trisulfide bonds in proteins is inhibited by implementation of methods described herein during the cell culture production of such proteins. In another embodiment, monoclonal antibodies are produced by the methods described herein.
    Type: Grant
    Filed: October 1, 2010
    Date of Patent: April 14, 2015
    Assignee: Biogen Idec Ma Inc.
    Inventors: David Evans, R. Blake Pepinsky, Dingyi Wen, Rashmi Rohit Kshirsagar, Karin Lucas
  • Patent number: 8986957
    Abstract: A cell culture medium with high content of choline chloride is provided. The cell culture media further comprise only moderate amounts of amino acids, in particular the amount of glutamine in the cell culture media is limited. The cell culture media can be used for large scale production of polypeptides using cell cultures. The cell culture media with high content of choline chloride are particularly suitable for fed-batch cell culture whereby cell viabilities stay at a higher level for a longer time and high polypeptide titers although limited amounts of amino acids are used.
    Type: Grant
    Filed: April 25, 2011
    Date of Patent: March 24, 2015
    Assignee: Novartis AG
    Inventors: Wolfgang Ernst Gustav Budach, Helene C. Chassin, Kerstin Dorsch
  • Patent number: 8980579
    Abstract: Provided herein are methods for stable integration and/or expression of one or more recombinant polynucleotides in a host cell. The recombinant polynucleotides are typically integrated into the host genome at some native chromosomal integration sites. The integration can be mediated by homologous recombination or by using a hybrid recombinase targeting the specific chromosomal locations. The native chromosomal integration sites in the host cells, which support stable integration and strong transcription activities of foreign genes, are present within or adjacent to specific genes in the CHO genome, the ankyrin 2 gene (Ank2), cleavage and polydenylation specific factor 4 gene (Cpsf4), C-Mos gene, and Nephrocystin-1/Mal gene. Also provided are methods and nucleic acid molecules for inserting site-specific recombination sequences (chromosomal landing pads) into these specific chromosomal locations, engineered host cells containing chromosomal landing pads, methods and compositions (e.g., kits) therefore.
    Type: Grant
    Filed: April 5, 2012
    Date of Patent: March 17, 2015
    Assignee: The Scripps Research Institute
    Inventors: Vincent P. Mauro, Wei Zhou, Bruce Cunningham, Gerald M. Edelman
  • Patent number: 8962262
    Abstract: Methods for producing a protein extract from cells, such as cells containing viral proteins, are provided. In general terms, the methods involve: increasing the pH of the cells to a pH of at least about pH 10.0 to produce an intermediate composition, and then, in the presence of a non-ionic detergent, neutralizing the pH of the intermediate composition to produce the protein extract. Kits and compositions for practicing the subject methods are also provided.
    Type: Grant
    Filed: May 11, 2007
    Date of Patent: February 24, 2015
    Assignees: Arbor Vita Corporation, Becton, Dickinson and Company
    Inventors: Stephen Lovell, Lydia Blank, Virginia Crews, Nancy Hasse, Peter Lu, Johannes Schweizer, John Mantlo
  • Patent number: 8957194
    Abstract: Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.
    Type: Grant
    Filed: May 8, 2012
    Date of Patent: February 17, 2015
    Assignee: Merck Sharpe & Dohme Corp.
    Inventors: Jon H. Condra, Rose M. Cubbon, Holly A. Hammond, Timothy McCabe, Shilpa Pandit, Laurence B. Peterson, Joseph C. Santoro, Ayesha Sitlani, Dana D. Wood, Henryk Mach, Heidi Pixley, Sonia M. Gregory, Jeffrey T. Blue, Kevin Wang, Peizhi (Peter) Luo, Denise K. Nawrocki, Pingyu Zhong, Feng Dong, Yan Li
  • Patent number: 8945867
    Abstract: The present invention relates to a process for producing a desired polypeptide using rat cells. Specifically, the present invention relates to a process for producing the polypeptide which comprises culturing rat cells such as YB2/3HL.P2.G11.16Ag.20 (hereinafter referred to as YB2/0), preferably rat cells to which a recombinant DNA comprising DNA encoding a desired polypeptide such as an immunologically functional molecule is introduced, in a medium which does not contain serum (hereinafter referred to as a serum-free medium). Among the desired polypeptides obtained by the process of the present invention, an antibody obtained by using a transformant of YB2/0 has a high antibody-dependent cell-mediated cytotoxic activity (hereinafter sometimes referred to as ADCC activity) and is useful as a pharmaceutical agent.
    Type: Grant
    Filed: February 2, 2009
    Date of Patent: February 3, 2015
    Assignee: Kyowa Hakko Kirin Co., Ltd.
    Inventors: Tatsuya Ogawa, Yoshinobu Konno, Naohisa Akashi, Hiroshi Takasugi, Seiji Sugimoto, Keiichi Yano
  • Publication number: 20150023908
    Abstract: The present invention relates to skin care compositions, including cosmeceuticals, for topical application, and more particularly, a skin cream, comprising exosomes and cell culture medium conditioned by cells grown in two-dimensional culture. Also included are methods of making and using such compositions and kits comprising the skin cream therein.
    Type: Application
    Filed: July 18, 2013
    Publication date: January 22, 2015
    Inventor: Ahmed H. Al-Qahtani
  • Patent number: 8927269
    Abstract: The present invention provides an Avian adeno-associated virus (AAAV) virus and vectors and particles derived therefrom. In addition, the present invention provides methods of delivering a nucleic acid to a cell using the AAAV vectors and particles. Methods of isolating the AAAV are provided.
    Type: Grant
    Filed: May 18, 2004
    Date of Patent: January 6, 2015
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Ioannis Bossis, John A. Chiorini
  • Patent number: 8911964
    Abstract: The invention describes improved methods and compositions for producing a recombinant protein, e.g., an antibody, in mammalian cell culture. In addition, the invention provides improved cell culture media, including improved production media, feed solutions, and combination feeds, which may be used to improve protein productivity in mammalian cell culture.
    Type: Grant
    Filed: March 26, 2014
    Date of Patent: December 16, 2014
    Inventors: Itzcoatl A. Pla, Joseph G. Matuck, John C. Fann, Christof Schulz, Nichole A. Roy, David F. Bruton, James McIntire, Yu-Hsiang David Chang, Thomas Seewoester
  • Patent number: 8906646
    Abstract: The invention describes improved methods and compositions for producing a recombinant protein, e.g., an antibody, in mammalian cell culture. In addition, the invention provides improved cell culture media, including improved production media, feed solutions, and combination feeds, which may be used to improve protein productivity in mammalian cell culture.
    Type: Grant
    Filed: March 26, 2014
    Date of Patent: December 9, 2014
    Assignee: AbbVie Inc.
    Inventors: Itzcoatl A. Pla, Joseph G. Matuck, John C. Fann, Christof Schulz, Nichole A. Roy, David F. Bruton, James McIntire, Yu-Hsiang David Chang, Thomas Seewoester
  • Publication number: 20140342389
    Abstract: A protein transduction method for efficiently delivery of exogenous proteins into mammalian cells is invented, which has the capability of targeting different cellular compartments and protection from degradation of the delivered proteins from cellular proteases. A composition for treat proteins has cation reagents, lipids and enhancers in a carrier. The method can be used in a number of ways including: production of large quantities of properly folded, post-translationally modified proteins using mammalian cell machinery, a in-cell fluorescence spectroscopy and imaging using small molecule fluorophores and a in-cell NMR spectroscopy using living mammalian cells. The method permits cell biology at atomic resolution that is physiologically and pathological relevant and permits protein therapy to treat human diseases. The method can also be used to deliver exogenous protein inside mammalian cells, wherein the exogenous proteins follow a similar secretion pathway as that of the endogenous protein.
    Type: Application
    Filed: April 25, 2014
    Publication date: November 20, 2014
    Applicant: WAYNE STATE UNIVERSITY
    Inventors: Jianjun Wang, Qianqian Li
  • Patent number: 8883450
    Abstract: A use of a signal peptide for producing a recombinant polypeptide of interest in an expression system, the signal peptide includes at least 12 amino acids of formula (I): (X1)iX2X3X4SX5X6X7, wherein: X1 is a peptide containing from 3 to 6 amino acids, i equal to 0 or 1, X2 is a peptide containing from 3 to 9 hydrophobic amino acids, X3 is a peptide containing from 3 to 5 amino acids, the peptide including at least 3 contiguous or non-contiguous leucines X4 is a peptide containing from 2 to 5 amino acids chosen from Ala, Thr, Ser, Gln, Ile, Met, X5 is Ala or Val, X6 is Gln, Asn or His, X7 is Ala or Cys, provided that when the signal peptide originates from a natural precursor of a specific protein, the polypeptide of interest is different from the protein.
    Type: Grant
    Filed: March 17, 2011
    Date of Patent: November 11, 2014
    Assignee: Laboratoire Francais du Fractionnement et des Biotechnologies
    Inventor: Alexandre Fontayne
  • Patent number: 8883446
    Abstract: The present invention relates to an eukaryotic expression vector comprising a nucleotide sequence encoding for the human long pentraxin PTX3 protein under the control of an effective promoter and a nucleotide sequence encoding for a selectable marker, recombinant human cell able to provide expression of proteins encoded by the vector and method for the production of the human long pentraxin PTX3 protein.
    Type: Grant
    Filed: July 20, 2010
    Date of Patent: November 11, 2014
    Assignee: Sigma-Tau Industrie Farmaceutiche Riunite, S.p.A.
    Inventors: Marica Sassano, Adelaide Esposito, Vincenzo Rivieccio, Giovanni Cassani
  • Publication number: 20140328916
    Abstract: A bioscaffold made from an isolated cardiac fibroblast-derived 3-dimensional extracellular matrix (ECM) is disclosed. The bioscaffold can be used as an epicardial patch for the delivery of therapeutic cells into myocardial tissue. Methods of making the 3-dimensional extracellular matrix using cultured cardiac fibroblasts are also disclosed.
    Type: Application
    Filed: July 14, 2014
    Publication date: November 6, 2014
    Inventors: Eric G. Schmuck, Kurt W. Saupe
  • Publication number: 20140322758
    Abstract: The present invention provides, among other things methods of increasing cell density, viability and/or titer in a cell culture including steps of adding a composition comprising iron to the cell culture.
    Type: Application
    Filed: October 9, 2012
    Publication date: October 30, 2014
    Inventors: Wenge Wang, Yen-Tung Luan, Denis Drapeau
  • Publication number: 20140308707
    Abstract: The present invention relates to methods of producing a Factor VIII polypeptide in mammalian cell cultures.
    Type: Application
    Filed: November 2, 2012
    Publication date: October 16, 2014
    Inventors: Laust Bruun Johnsen, Mille Petersen Kolind, Peder Lisby Noerby
  • Patent number: 8859229
    Abstract: A method of mRNA production for use in transfection is provided, that involves in vitro transcription of PCR generated templates. This RNA can efficiently transfect different kinds of cells. This approach results in increased efficiency (fidelity and productivity) of mRNA synthesis and is less time consuming because it does not require cloning, and also consequently eliminates the unwanted errors and effects related to RNA made on DNA templates obtained with cloning techniques. The results of transfection of RNAs demonstrate that RNA transfection can be very effective in cells that are exceedingly difficult to transfect efficiently with DNA constructs. The method can be used to deliver genes into cells not- or only poorly transfectable for DNA, in vitro and in vivo.
    Type: Grant
    Filed: February 4, 2008
    Date of Patent: October 14, 2014
    Assignee: Yale University
    Inventors: Peter M. Rabinovich, Sherman M. Weissman, Marina E. Komarovskaya, Erkut Bahceci
  • Patent number: 8852435
    Abstract: An assembly capable of capturing and purifying expressed biological products during or at the end of a bioreaction cycle is disclosed wherein a binding resin is kept separated from the contents of the bioreactor allowing capturing, harvesting and purification of biological products in a bioreactor; the invention additionally provides means of removing undesirable metabolic products as well as provides for efficient loading of chromatography columns.
    Type: Grant
    Filed: November 29, 2011
    Date of Patent: October 7, 2014
    Assignee: Therapeutics Proteins International, LLC
    Inventor: Sarfaraz Niazi
  • Publication number: 20140295495
    Abstract: The present invention pertains to methods of preventing and eliminating trisulfide bonds in proteins such as antibodies. In one embodiment, trisulfide bonds in proteins are converted to disulfide bonds as part of chromatographic purification procedures. In another embodiment, the formation of trisulfide bonds in proteins is inhibited by implementation of methods described herein during the cell culture production of such proteins. In another embodiment, monoclonal antibodies are produced by the methods described herein.
    Type: Application
    Filed: May 11, 2012
    Publication date: October 2, 2014
    Applicant: Biogen Idec MA Inc.
    Inventors: Rashmi Rohit Kshirasagar, Alan Gilbert
  • Patent number: 8846385
    Abstract: Lentiviral vectors modified at the 5? LTR or both the 5? and 3? LTR's are useful in the production of recombinant lentivirus vectors. Such vectors can be produced in the absence of a functional tat gene. Multiple transformation of the host cell with the vector carrying the transgene enhances virus production.
    Type: Grant
    Filed: July 26, 2006
    Date of Patent: September 30, 2014
    Assignee: GBP IP, LLC
    Inventors: Luigi Naldini, Thomas Dull, Deborah A. Farson, Rochelle Witt
  • Patent number: 8841089
    Abstract: The present invention relates to polynucleotides comprising a first nucleic acid sequence for a chromatin element, which is capable of enhancing expression, and at least one second nucleic acid sequence comprising a curved origin motif. Furthermore, the invention relates to a host cell, a non-human transgenic organism, a vector and a kit comprising the aforementioned polynucleotide. Moreover, the invention relates to methods for expressing a polynucleotide of interest.
    Type: Grant
    Filed: March 28, 2008
    Date of Patent: September 23, 2014
    Assignee: Hochschule Mannheim
    Inventors: Manfred Frey, Heiko Flammann, Mathias Hafner
  • Patent number: 8841126
    Abstract: Disclosed is a method for introducing a gene into a target cell using a retrovirus vector, which is simple and highly efficient. Specifically disclosed is a method for introducing a gene into a target cell using a retrovirus vector, which comprises the steps of (a) placing a liquor containing a retrovirus vector having a foreign gene carried thereon into a culture vessel on which a retrovirus-binding substance has been immobilized, and incubating the liquor at a temperature lower than 25° C. for 4 hours or longer, thereby producing a culture vessel having the retrovirus vector bound thereto, and (b) adding a target cell to the culture vessel that has been produced in step (a) and incubating the culture vessel. The gene introduction method is simple and highly efficient, and is useful particularly in the fields of medicine, cell technology, gene technology, embryologic technology and the like.
    Type: Grant
    Filed: June 29, 2011
    Date of Patent: September 23, 2014
    Assignee: Takara Bio Inc.
    Inventors: Katsuyuki Dodo, Naoki Saito, Hideto Chono, Junichi Mineno